既往生物制剂使用对布罗达鲁单抗与乌司奴单抗治疗中重度斑块状银屑病疗效和安全性的影响:随机对照试验AMAGINE-2和AMAGINE-3的整合分析
整合分析两项安慰剂和乌司奴单抗对照的III期试验,评估既往生物制剂暴露对布罗达鲁单抗和乌司奴单抗疗效与安全性的影响。结果显示布罗达鲁单抗210 mg每2周疗效不受既往生物制剂暴露影响,第12周PASI 100应答率约为乌司奴单抗的两倍,两者耐受性相似。
要点
- 布罗达鲁单抗210 mg每2周在既往生物制剂经治与初治患者中PASI 100应答率相似。
- 第12周布罗达鲁单抗PASI 100应答率约为乌司奴单抗的两倍。
- 两者耐受性相似,似不受既往生物制剂治疗影响。
核心结论
- 布罗达鲁单抗210 mg每2周疗效不受既往生物制剂治疗影响,PASI 75、90和100的P值分别为0.31、0.32和0.64。
- 第12周布罗达鲁单抗实现PASI 100或完全清除的患者数约为乌司奴单抗的两倍,既往生物制剂失败者差异最明显。
- 两种治疗均耐受良好。
研究设计与样本
- 两项安慰剂和乌司奴单抗对照的III期临床试验的整合分析。
- 初始12周诱导期,患者接受布罗达鲁单抗210 mg或140 mg每2周、乌司奴单抗或安慰剂治疗。
- 共493例患者有既往生物制剂使用史,其中布罗达鲁单抗210 mg每2周组334例(27%),乌司奴单抗组159例(26%)。
- 分别有150例(12%)和62例(10%)报告既往生物制剂治疗失败。
主要发现
- 第12周,生物制剂初治和经治患者中分别有40.9%和39.5%达到PASI 100,乌司奴单抗组分别为21.1%和17.0%(均P < 0.001)。
- 既往生物制剂成功或失败的患者中,分别有41.7%和32.0%达到PASI 100,乌司奴单抗组分别为21.1%和11.3%。
- 耐受性相似,似不受既往生物制剂治疗影响。
关键数值与推荐
- 疗效终点包括PASI 75、静态医生总体评估(评分0或1)对比安慰剂、PASI 100对比乌司奴单抗、皮肤病生活质量指数和银屑病症状量表。
- 布罗达鲁单抗210 mg每2周在既往生物制剂经治与初治患者中PASI 100应答率分别为39.5%和40.9%。
- 乌司奴单抗在既往生物制剂经治与初治患者中PASI 100应答率分别为17.0%和21.1%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biologics are being used increasingly to treat moderate-to-severe psoriasis. Efficacy may differ in patients with previous exposure to biologics. OBJECTIVES: To investigate the impact of previous biologic exposure on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis. METHODS: Two placebo- and ustekinumab-controlled phase III clinical trials. There was an initial 12-week induction phase where patients were treated with brodalumab [210 mg or 140 mg every 2 weeks (Q2W)], ustekinumab or placebo. Efficacy end points included ≥ 75% improvement in Psoriasis Area and Severity Index (PASI 75) and static Physician's Global Assessment (score of 0 or 1) vs. placebo, PASI 100 vs. ustekinumab, Dermatology Life Quality Index and Psoriasis Symptom Inventory. Adverse events were monitored throughout. RESULTS: In total, 493 patients [334 (27%) brodalumab 210 mg Q2W and 159 (26%) ustekinumab] had received prior biologics; 150 (12%) and 62 (10%), respectively, reported previously failed treatment with a biologic. Brodalumab efficacy in patients with or without previous exposure to biologics was statistically equivalent: 40·9% and 39·5% of biologic-naive and -experienced patients achieved PASI 100 at week 12, compared with 21·1% and 17·0% with ustekinumab (both P < 0·001). In patients where prior biologics had been successful or failed, 41·7% and 32·0% achieved PASI 100, compared with 21·1% and 11·3% with ustekinumab. Tolerability was similar, and did not appear to be influenced by previous treatment with biologics. CONCLUSIONS: The efficacy of brodalumab 210 mg Q2W was similar regardless of prior biological therapy (P = 0·31, 0·32 and 0·64 for PASI 75, 90 and 100, respectively). Almost twice as many patients achieved PASI 100 or complete clearance with brodalumab at week 12 compared with ustekinumab; the differences were most noticeable where previous biologics had failed. Both treatments were well tolerated.
引用
- Papp KA, Gordon KB, Langley RG, et al. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. Br J Dermatol. 2018. PMID: 29488226. doi:10.1111/bjd.16464
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。